MA31977B1 - Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci - Google Patents

Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci

Info

Publication number
MA31977B1
MA31977B1 MA32608A MA32608A MA31977B1 MA 31977 B1 MA31977 B1 MA 31977B1 MA 32608 A MA32608 A MA 32608A MA 32608 A MA32608 A MA 32608A MA 31977 B1 MA31977 B1 MA 31977B1
Authority
MA
Morocco
Prior art keywords
novel antibodies
met dimerization
antibodies inhibiting
met
inhibiting
Prior art date
Application number
MA32608A
Other languages
Arabic (ar)
English (en)
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31977(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA31977B1 publication Critical patent/MA31977B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé permettant la sélection d'anticorps anti-c-met capables d'
MA32608A 2007-07-12 2010-02-10 Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci MA31977B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
EP07301231A EP2014681A1 (fr) 2007-07-12 2007-07-12 Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US2063908P 2008-01-11 2008-01-11
PCT/EP2008/059026 WO2009007427A2 (fr) 2007-07-12 2008-07-10 Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA31977B1 true MA31977B1 (fr) 2011-01-03

Family

ID=38871713

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32608A MA31977B1 (fr) 2007-07-12 2010-02-10 Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci

Country Status (35)

Country Link
US (6) US8329173B2 (fr)
EP (6) EP2014681A1 (fr)
JP (4) JP5562844B2 (fr)
KR (4) KR101701685B1 (fr)
CN (4) CN103183739B (fr)
AR (4) AR067517A1 (fr)
AU (1) AU2008274171B2 (fr)
BR (1) BRPI0815564B8 (fr)
CA (4) CA2981821C (fr)
CL (1) CL2008002015A1 (fr)
CO (1) CO6170364A2 (fr)
CY (1) CY1116608T1 (fr)
DK (1) DK2188312T3 (fr)
ES (5) ES2678495T3 (fr)
HR (1) HRP20150887T1 (fr)
HU (1) HUE026026T2 (fr)
IL (5) IL203114A (fr)
MA (1) MA31977B1 (fr)
ME (1) ME02341B (fr)
MX (3) MX353449B (fr)
MY (1) MY158756A (fr)
NZ (4) NZ599958A (fr)
PA (1) PA8789201A1 (fr)
PH (3) PH12018502039A1 (fr)
PL (1) PL2188312T3 (fr)
PT (1) PT2188312E (fr)
RS (1) RS54197B1 (fr)
RU (1) RU2552161C2 (fr)
SA (1) SA08290423B1 (fr)
SG (1) SG183015A1 (fr)
SI (1) SI2188312T1 (fr)
TN (1) TN2010000016A1 (fr)
TW (4) TWI602829B (fr)
WO (1) WO2009007427A2 (fr)
ZA (1) ZA201000966B (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
CN102361884A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
CN102378768A (zh) 2009-04-07 2012-03-14 罗氏格黎卡特股份公司 双特异性抗-ErbB-3/抗-c-Met抗体
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
EP3904391B1 (fr) * 2010-03-10 2024-07-10 Genmab A/S Anticorps monoclonaux contre c-met
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
EP2402370A1 (fr) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Nouvel anticorps pour le diagnostic et/ou le pronostic du cancer
EP2588107A1 (fr) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
KR20140019284A (ko) * 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (fr) 2010-09-30 2012-04-05 Ablynx Nv Matières biologiques associées à c-met
EP3165538A1 (fr) 2010-11-03 2017-05-10 Argen-X Nv Anticorps anti c-met
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
CA3141978A1 (fr) 2011-06-23 2012-12-27 Ablynx Nv Techniques permettant de predire, detecter et reduire une interference proteinique specifique dans des dosages impliquant des domaines variables uniques d'immunoglobuline
LT3466972T (lt) * 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
RU2013155695A (ru) * 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
WO2013033008A2 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispécifiques à fc en tandem
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
EP2758430A4 (fr) 2011-09-20 2015-06-03 Lilly Co Eli Anticorps anti-c-met
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN106046161B (zh) * 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (fr) 2011-11-03 2014-09-10 Argen-X B.V. Antigenes chimeres humains chameaux et leur utilisation
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
WO2013079973A1 (fr) 2011-12-02 2013-06-06 Di Cara Danielle Marie Anticorps dirigés contre le récepteur de hgf et leurs utilisations
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
WO2013130565A1 (fr) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Anticorps de neutralisation pour une maladie associée au virus d'epstein-barr
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
HK1208181A1 (en) 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
JP2015535212A (ja) * 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP5614733B2 (ja) * 2012-09-05 2014-10-29 Jsr株式会社 細胞の上皮性維持に作用する物質のスクリーニング方法
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
EP2727941A1 (fr) 2012-11-05 2014-05-07 MAB Discovery GmbH Procédé pour la production d'anticorps multispécifiques
WO2014067642A1 (fr) 2012-11-05 2014-05-08 Mab Discovery Gmbh Procédé de fabrication d'anticorps plurispécifiques
WO2014074907A1 (fr) * 2012-11-09 2014-05-15 Indi Molecular, Inc. Agents de capture spécifiques de c-met, compositions et procédés d'utilisation et de fabrication
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
WO2014128235A1 (fr) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Méthodes de traitement du cancer et de prévention de résistance aux médicaments
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031626A1 (fr) 2013-08-28 2015-03-05 Abbvie Inc. Dosage de cmet soluble
WO2015031614A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de la cmet soluble
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
JP2018503596A (ja) 2014-10-03 2018-02-08 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｔｄｐ−４３の病理学的形態に対する抗体及びその使用
WO2016053610A1 (fr) * 2014-10-03 2016-04-07 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
US11035860B2 (en) * 2014-11-20 2021-06-15 Stichting Katholieke Universiteit Auto-active and intracellular mutant of MET
EP3229836B1 (fr) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Anticoprs monoclonaux contre 'axl'
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
KR20170136536A (ko) * 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
ES3029413T3 (en) 2015-04-02 2025-06-24 Ablynx Nv Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US20190194345A1 (en) * 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
WO2017173091A1 (fr) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Méthodes pour le traitement et le diagnostic du cancer par le ciblage d'une protéine à prédominance de répétitions de glycoprotéine a (garp) et la mise en œuvre d'une immunothérapie efficace seule ou en association
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
JP7120989B2 (ja) * 2016-07-06 2022-08-17 セルジーン コーポレイション 低免疫原性を有する抗体及びその使用
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
US11525004B2 (en) 2017-07-20 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Recombinant CD123-binding antibodies
WO2019117691A1 (fr) * 2017-12-15 2019-06-20 경북대학교 산학협력단 Peptides se liant à cd44v6 et utilisation correspondante
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
EP4534560A3 (fr) * 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Animaux non humains génétiquement modifiés pour générer des anticorps thérapeutiques contre des complexes peptide-mhc, leurs procédés de fabrication et utilisations
CA3098103A1 (fr) 2018-05-23 2019-11-28 Adc Therapeutics Sa Adjuvant moleculaire
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
CA3131096A1 (fr) 2019-04-05 2020-10-08 Chi-Huey Wong Saccharide resistant a la sialidase, son procede de production et son utilisation
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CA3182526A1 (fr) 2020-05-08 2021-11-11 Academia Sinica Vaccins de la grippe chimerique
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN116783220A (zh) * 2020-12-16 2023-09-19 武汉友芝友生物制药股份有限公司 抗bcma抗体及其制备方法和应用
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
EP4319811A1 (fr) 2021-04-06 2024-02-14 Abbvie Biotherapeutics Inc. Méthodes de traitement du cancer du poumon non à l'aide de telisotuzumab vedotin
WO2022221837A2 (fr) 2021-04-12 2022-10-20 Academia Sinica Vaccin à coronavirus amélioré
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
KR20240099302A (ko) * 2021-11-05 2024-06-28 치아타이 티안큉 파마수티컬 그룹 주식회사 c-Met에 결합하는 항체 및 이의 용도
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
CA3268566A1 (fr) 2023-04-08 2024-10-17 Rock Biomedical Inc. Procédés et compositions pour une distribution ciblée par des polymersomes
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1476120B1 (fr) * 2002-02-21 2010-09-29 Duke University Methodes therapeutiques utilisant des anticorps anti-cd22
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (fr) * 2004-08-05 2010-12-31 Genentech Inc Antagonistes anti-cmet humanises
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
EP1851248B1 (fr) * 2005-02-10 2016-08-10 Baylor Research Institute Anticorps monoclonaux anti-interferon alpha et procedes d'utilisation
CA2606102C (fr) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere"
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
ES2368864T3 (es) 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
WO2010064089A1 (fr) 2008-12-02 2010-06-10 Pierre Fabre Medicament Nouvel anticorps anti-cmet
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)

Also Published As

Publication number Publication date
HUE026026T2 (en) 2016-05-30
ES2686693T3 (es) 2018-10-19
MX353449B (es) 2018-01-08
TWI549965B (zh) 2016-09-21
US8329173B2 (en) 2012-12-11
ES2678495T3 (es) 2018-08-13
CN101981054B (zh) 2015-04-15
JP2014113153A (ja) 2014-06-26
WO2009007427A2 (fr) 2009-01-15
MX345391B (es) 2017-01-27
PH12018502039A1 (en) 2019-08-19
US9107907B2 (en) 2015-08-18
CA2888691A1 (fr) 2009-01-15
KR20100044212A (ko) 2010-04-29
KR101701685B1 (ko) 2017-02-01
RU2552161C2 (ru) 2015-06-10
AR109660A2 (es) 2019-01-09
US20100115639A1 (en) 2010-05-06
TW201605892A (zh) 2016-02-16
TN2010000016A1 (en) 2011-09-26
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
SA08290423B1 (ar) 2013-12-23
IL223105B (en) 2020-02-27
EP2415784A1 (fr) 2012-02-08
TWI592427B (zh) 2017-07-21
IL223108A0 (en) 2012-12-31
CN103183739B (zh) 2016-08-17
EP2535357A1 (fr) 2012-12-19
EP2415785A1 (fr) 2012-02-08
US20150252114A1 (en) 2015-09-10
US20140010818A1 (en) 2014-01-09
US8871910B2 (en) 2014-10-28
IL223108B (en) 2019-06-30
AR109535A2 (es) 2018-12-19
CA2982484C (fr) 2021-06-01
JP2014113154A (ja) 2014-06-26
JP5889925B2 (ja) 2016-03-22
RU2010104633A (ru) 2011-08-20
EP2188312B1 (fr) 2015-05-27
HRP20150887T1 (hr) 2015-09-25
US20130280257A1 (en) 2013-10-24
HK1193620A1 (zh) 2014-09-26
PL2188312T3 (pl) 2016-01-29
PH12018502040A1 (en) 2019-08-19
ES2693542T3 (es) 2018-12-12
CA2694418C (fr) 2018-03-27
US8871909B2 (en) 2014-10-28
NZ613716A (en) 2015-01-30
IL203114A (en) 2015-03-31
IL223106A0 (en) 2012-12-31
AR109659A2 (es) 2019-01-09
NZ583041A (en) 2012-06-29
AU2008274171B2 (en) 2014-02-27
CN103509113A (zh) 2014-01-15
CY1116608T1 (el) 2017-03-15
TW201605891A (zh) 2016-02-16
CA2888691C (fr) 2023-01-03
AU2008274171A1 (en) 2009-01-15
JP5889924B2 (ja) 2016-03-22
IL223109B (en) 2019-06-30
PH12018502038A1 (en) 2019-08-19
CA2981821A1 (fr) 2009-01-15
IL223106B (en) 2020-06-30
AR067517A1 (es) 2009-10-14
EP2415785B1 (fr) 2018-04-25
CN101981054A (zh) 2011-02-23
WO2009007427A3 (fr) 2009-04-09
ME02341B (fr) 2015-12-31
KR101719084B1 (ko) 2017-03-22
EP2535356A1 (fr) 2012-12-19
US8889832B2 (en) 2014-11-18
JP5889923B2 (ja) 2016-03-22
HK1193619A1 (zh) 2014-09-26
MY158756A (en) 2016-11-15
CA2982484A1 (fr) 2009-01-15
JP2014113155A (ja) 2014-06-26
KR20160019974A (ko) 2016-02-22
PA8789201A1 (es) 2009-08-26
CN103509112B (zh) 2015-10-21
BRPI0815564B1 (pt) 2020-01-21
TWI602830B (zh) 2017-10-21
CA2981821C (fr) 2020-07-28
TWI602829B (zh) 2017-10-21
ZA201000966B (en) 2011-02-23
KR101625234B1 (ko) 2016-05-30
KR101701686B1 (ko) 2017-02-01
JP2010532982A (ja) 2010-10-21
US20130273060A1 (en) 2013-10-17
KR20150070451A (ko) 2015-06-24
PT2188312E (pt) 2015-10-05
HK1149024A1 (en) 2011-09-23
EP2535357B1 (fr) 2018-08-08
CL2008002015A1 (es) 2008-11-21
JP5562844B2 (ja) 2014-07-30
EP2014681A1 (fr) 2009-01-14
MX341012B (es) 2016-08-03
CN103183739A (zh) 2013-07-03
CN103509112A (zh) 2014-01-15
DK2188312T3 (en) 2015-08-03
EP2535356B1 (fr) 2018-06-13
TW201437231A (zh) 2014-10-01
BRPI0815564B8 (pt) 2021-05-25
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
NZ599958A (en) 2013-11-29
IL223105A0 (en) 2012-12-31
IL223109A0 (en) 2012-12-31
US20130272957A1 (en) 2013-10-17
SI2188312T1 (sl) 2015-09-30
CO6170364A2 (es) 2010-06-18
CA2694418A1 (fr) 2009-01-15
TW200911828A (en) 2009-03-16
SG183015A1 (en) 2012-08-30
CN103509113B (zh) 2015-10-21
RS54197B1 (sr) 2015-12-31
BRPI0815564A2 (pt) 2015-02-18
EP2188312A2 (fr) 2010-05-26
EP2415784B1 (fr) 2018-06-13

Similar Documents

Publication Publication Date Title
MA31904B1 (fr) Anticorps bispecifiques bivalents
MA31925B1 (fr) Anticorps bivalents bispécifiques
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
MA34488B1 (fr) Composition pesticides
UY32049A (es) Inhibidores de cmet
MA34641B1 (fr) Anticorps anti-il-23
EP1827366A4 (fr) Complexes stabilises de phosphate de calcium
UY35578A (es) Síntesis de compuestos de ester y ácido bórico
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
EP2134852A4 (fr) Procédés de génération d'anticorps
SV2010003502A (es) Fungicidas novedosos
EP2576616A4 (fr) Méthode de synthèse d'anticorps présentant des propriétés améliorées
EP2310882A4 (fr) Exploration utilisant des sources électromagnétiques verticales tractées en même temps que des récepteurs d exploration
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EP1999492A4 (fr) Méthode de gestion dynamique d'un système de production
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
CR10563A (es) Anticuerpos monoclonales ant-il-6 y usos de los mismos
MX2008008152A (es) Compuestos heterociclicos biciclicos.
EP2116642A4 (fr) Méthode de tricotage de la partie formant le talon de chaussettes
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
UY32108A (es) Compuestos de imidazol y de triazol, su uso, asi como productos que los contienen
SV2010003617A (es) Fungicidas
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
EP1951061A4 (fr) Méthode de modification de la texture d'une préparation